SU 9902

Drug Profile

SU 9902

Alternative Names: SU-9902

Latest Information Update: 03 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SUGEN; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics
  • Mechanism of Action Fibroblast growth factor receptor antagonists; Protein tyrosine kinase inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Glioma

Most Recent Events

  • 06 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
  • 21 Sep 1999 SUGEN has been acquired by Pharmacia & Upjohn
  • 28 May 1999 Preclinical development for Glioma in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top